Benefits of therapy by Dynamin 2 mutant specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy
Delphine Trochet
(1)
,
Bernard Prudhon
(1)
,
Lylia Mekzine
(1)
,
Mégane Lemaitre
(1)
,
Maud Beuvin
(1, 2)
,
Laura Julien
(1)
,
Sofia Benkhelifa-Ziyyat
(1)
,
Mai Thao Bui
(2)
,
Norma Romero
(2, 3, 1)
,
Marc Bitoun
(1)